Lexeo Therapeutics, Inc. (LXEO) Stock Price & Analysis
Lexeo Therapeutics, Inc. (LXEO) fell 1.06% to USD 4.66 as of July 25, 2026 at 02:21 UTC, according to Nexqual real-time market data.
LXEO last closed at USD 4.71; the session ranged USD 4.5–4.9 on volume of 643,489 shares. Market capitalization is $365.91M, with a 52-week range of USD 3.6–10.99 (NGM). Source: Nexqual, July 25, 2026 at 02:21 UTC.
Key Statistics (as of July 25, 2026 at 02:21 UTC)
| Price | USD 4.66 |
|---|---|
| Change | ▼ 1.06% (down) |
| Previous Close | USD 4.71 |
| Open | USD 4.72 |
| Day Range | USD 4.5 – 4.9 |
| 52-Week Range | USD 3.6 – 10.99 |
| Volume | 643,489 shares |
| Market Cap | $365.91M |
| Exchange | NGM |
Technical Analysis (LXEO)
Nexqual's technical model rates LXEO "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 02:21 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 50.49 (neutral) |
| vs SMA50 | Below (USD 4.78) |
| MACD | -0.04 (negative) |
Analyst Ratings (LXEO)
Wall Street analysts rate LXEO "None" based on 9 analysts, with a mean price target of USD 20.89 (range USD 9–30), per Nexqual as of July 25, 2026 at 02:21 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 20.89 |
| High Target | USD 30 |
| Low Target | USD 9 |
| Buy / Hold / Sell | 10 / 0 / 0 |
Earnings (LXEO)
| Next Earnings Date | 2026-08-13 |
|---|---|
| EPS Estimate | USD -0.28 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.25 vs est -0.3 ▲ beat |
| 2025-12-31 | USD -0.27 vs est -0.3 ▲ beat |
| 2025-09-30 | USD -0.33 vs est -0.46 ▲ beat |
| 2025-06-30 | USD -0.68 vs est -0.66 ▼ miss |
Source: Nexqual, July 25, 2026 at 02:21 UTC.
Financials & Fundamentals (LXEO)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -54.75% |
| Debt / Equity | 3.18 |
| Current Ratio | 14.16 |
| Total Cash | $193.04M |
| Total Debt | $7.37M |
| Free Cash Flow | $-67.34M |
Source: Nexqual, July 25, 2026 at 02:21 UTC.
Financial Health Score (LXEO)
Nexqual rates Lexeo Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 02:21 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $193M cash vs $7M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$98M |
| Efficiency | Critical — ROE -55%, ROA -32.5% |
Ownership (LXEO)
| Insider Ownership | +0.60% |
|---|---|
| Institutional Ownership | +114.54% |
| Shares Outstanding | 78.52M |
| Float | 47.33M |
| Short % of Float | +24.15% |
Source: Nexqual, July 25, 2026 at 02:21 UTC.
Leadership (LXEO)
Lexeo Therapeutics, Inc. is led by R. Nolan Townsend (age 44), CEO & Director, per Nexqual as of July 25, 2026 at 02:21 UTC.
| CEO & Director | R. Nolan Townsend (age 44) |
|---|---|
| CFO & Principal Accounting Officer | Louis Tamayo (age 48) |
| Co-Founder, Chief Scientific Advisor & Member of Scientific Advisory Board | Ronald G. Crystal |
| Chief Operating Officer | Jose Manuel Otero (age 46) |
| Senior Vice President of Regulatory Affairs | Keith Wonnacott |
Major Backers & Investors (LXEO)
Notable institutional backers of Lexeo Therapeutics, Inc. include Paradigm Biocapital Advisors LP, Affinity Asset Advisors, Llc, RA Capital Management, L.P., according to Nexqual as of July 25, 2026 at 02:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Paradigm Biocapital Advisors LP | 7.88% |
| Affinity Asset Advisors, Llc | 6.43% |
| RA Capital Management, L.P. | 6.37% |
| Janus Henderson Group PLC | 6.34% |
| Vestal Point Capital, LP | 5.7% |
| Frazier Life Sciences Management, L.P. | 5.64% |
| Citadel | 4.88% |
| Orbimed Advisors LLC. | 4.59% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.83% |
| State Street | 8.34% |
Source: Nexqual, July 25, 2026 at 02:21 UTC.
From Lexeo Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States.
- The company is also developing LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy.
- In addition, it is developing LX1001, LX1020, and LX1021, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MLYS | Mineralys Therapeutics, Inc. | USD 26.71 | ▼ 1.11% |
| NGNE | Neurogene Inc. | USD 34.9 | ▼ 3.35% |
| KYTX | Kyverna Therapeutics, Inc. | USD 7.41 | ▲ 0.14% |
| LRMR | Larimar Therapeutics, Inc. | USD 4 | ▼ 0.5% |
| PEPG | PepGen Inc. | USD 1.93 | ▲ 0.52% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 02:21 UTC. This page is informational and not investment advice.